Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gifu
Clinical trial register · Japan

Clinical Trials in Gifu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC12 GlaxoSmithKline12 AstraZeneca9 Hoffmann-La Roche5 Novartis Pharmaceuticals5
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Gifu

103 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Hoffmann-La Roche
Phase 3
400
Gifu, Hyōgo
2026-10-06
Not yet open
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
NCT07753005Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage
Aesculap AG
Observational
176
Nagoya, Toyoake, Kashiwa, Gifu, Sapporo, Nishinomiya, Kawasaki, Kashihara
2026-09-30
Not yet open
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
NCT07870837Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT)
iRhythm Technologies, Inc.
Not applicable
130
Gifu, Nagoya
2026-09-30
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Nagoya, Gifu, Bunkyo Ku, Kodaira, Yonago
2026-06-03
Recruiting
Takeda
Phase 3
300
Nagoya, Fukushima, Gifu, Fukuyama-shi, Amagasaki-shi, Mibu, Bunkyo-ku, Shinagawa-ku
2026-05-21
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
Aichi Medical University
Not applicable
90
Aichi, Gifu
2026-04-15
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Aichi Medical University
Not applicable
120
Aichi, Gifu
2025-11-20
Recruiting
Summit Therapeutics
Phase 3
600
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Recruiting
AstraZeneca
Phase 2
435
Bunkyō City, Gifu, Hiratsuka-shi, Kamogawa-shi, Kiyose-shi, Kurashiki-shi, Meguro-ku, Miyazaki
2025-11-06
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
GlaxoSmithKline
Phase 3
1,200
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
2025-10-24
Recruiting
GlaxoSmithKline
Phase 3
1,196
Gifu, Mie, Tokyo
2025-10-20
Recruiting
Eli Lilly and Company
Phase 3
4,500
Amagasaki, Asahikawa, Bunkyō, Bunkyō City, Chikushino-shi, Fukuoka, Gifu, Ginowan
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Akita, Amagasaki, Bunkyō, Chūōku, Fujisawa, Fukuoka, Gifu, Hachioji-shi
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Not yet open
Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis
NCT07106346Walled Off Necrosis, Pancreatitis, Acute Necrotic Collection, Necrotizing Pancreatitis
Tokyo University
Not applicable
224
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kagawa, Kagoshima
2025-08-05
Recruiting
Yukinori Ozaki
Phase 2
24
Nagoya, Kashiwa-shi, Gifu, Hiroshima, Sapporo, Akashi-shi, Okayama, Osaka
2025-06-24
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Recruiting
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT07125417Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
OCEAN-SHD Study Group
Phase 4
500
Nagoya, Toyohashi, Matsudo, Kitakyushu, Gifu, Sapporo, Isehara, Kawasaki
2025-05-29
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
AstraZeneca
Phase 3
990
Akashi-shi, Chikushino-shi, Chiyoda-ku, Fukui-shi, Fukuoka, Gifu, Iruma-Gun, Ishinomaki
2025-03-25
Recruiting
Daiichi Sankyo
Phase 3
726
Bunkyō City, Chūōku, Gifu, Hiroshima, Kashiwa-shi, Kitakyushu, Kochi, Kōtoku
2025-02-27
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
Active, closed
H. Lundbeck A/S
Phase 3
401
Nagoya, Toyoake-Shi, Gifu, Sapporo, Sendai, Niigata, Iruma-shi, Bunkyō City
2024-12-03
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Akashi-shi, Takamatsu, Chuo Ku, Chuo-ku Osaka-shi, Gifu, Hamamatsu, Hiroshima, Izumi-shi
2024-11-22
Active, closed
Daiichi Sankyo
Phase 3
700
Akita, Aomori, Bunkyō City, Chiba, Fukuoka, Fukuyama, Gifu, Hamamatsu
2024-11-19
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
Chiba, Fuchū, Gifu, Niigata, Sagamihara, Sanda-shi, Sendai
2024-10-02
Active, closed
Hoffmann-La Roche
Phase 3
400
Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki
2024-09-17
Recruiting
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
NCT05485766Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer
DrugsOlaparib·Keytruda·Paclitaxel·Carboplatin
Okayama University
Phase 2
23
Gifu, Okayama, Tokyo
2024-07-16
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Kashiwa-shi, Matsuyama, Gifu, Ota-Shi, Kure, Sapporo, Fukuoka, Akashi
2024-06-30
Active, closed
AbbVie
Phase 3
421
Anjo, Nagoya, Chiba, Yoshida-gun, Fukuoka, Gifu, Maebashi, Fukuyama
2024-05-19
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
20
Nagoya, Akita, Urayasu-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Fukushima, Gifu
2024-05-17
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Active, closed
AbbVie
Phase 2
156
Gamagori-shi, Nagakute, Kashiwa-shi, Urayasu-shi, Kitakyushu-shi, Fukushima, Gifu, Ogaki-shi
2024-03-23
Active, closed
GlaxoSmithKline
Phase 4
336
Gifu, Kagawa, Tokyo
2024-03-20
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Maebashi, Sapporo, Hizume, Kawasaki, Yokohama, Ehime, Fukuoka, Gifu
2024-03-13
Recruiting
Zephyr Valve Japan Post-Marketing Surveillance
NCT06332885Emphysema, COPD, Severe Emphysema
Pulmonx Corporation
Observational
140
Aichi, Gifu, Kanagawa, Kanazawa, Kawasaki, Mie, Nagasaki, Nagoya
2024-03-12
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Fukuoka, Fukutsu, Gifu, Ginowan, Gunma, Hokkaido, Isehara, Itabashi Ku
2024-01-17
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Fukuoka, Gifu, Izumi-shi, Ōta-ku, Sendai
2023-12-20
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Not yet open
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
NCT06133023Pancreatic Fluid Collection, Pancreatitis, Pancreatic Pseudocyst
Tokyo University
Not applicable
80
Aichi, Bunkyō-Ku, Tokyo, Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima
2023-11
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto
2023-09-18
Recruiting
Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula
NCT07862088Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula
Tokyo University
Observational
5,000
Ōtsu, Bunkyō-Ku, Tokyo, Gifu, Hyōgo, Kawagoe, Kobe, Ōsaka-sayama
2023-09-14
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Sapporo, Kobe, Yokohama, Sendai, Matsumoto, Mitaka, Gifu
2023-08-22
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Shibukawa-shi, Kamakura-Shi, Kumamoto, Sunto-gun, Chiba, Gifu, Hiroshima, Isehara-shi
2023-06-22
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
Fukuyama, Gifu, Ichinomiya, Kobe, Matsudo, Osaka, Tokyo
2023-06-21
Recruiting
Daiichi Sankyo
Phase 1
128
Gifu, Osaka, Tokyo
2023-05-30
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Aichi, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Funabashi-shi, Gifu, Higashiibaraki-gun
2023-04-11
Active, closed
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
AstraZeneca
Observational
416
Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma
2023-04-04
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Bunkyō City, Chiba, Gifu, Gunma, Hirakata, Hitachi, Iruma-gun, Kamogawa
2023-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu, Hatsukaichi, Hidaka
2023-02-15
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Nagakute, Shibukawa, Sapporo, Okayama, Iruma-gun, Chiba, Fukuoka, Gifu
2023-02-03
Active, closed
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562Diffuse Large B-Cell Lymphoma
Tanabe Pharma Corporation
Phase 1/2
46
Nagoya, Kashiwa-shi, Fukuoka, Iizuka-shi, Fukushima, Gifu, Ota-shi, Sapporo
2023-01-30
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Narita, Matsuyama, Gifu, Kobe, Isehara, Suita, Itabashi-ku, Shinjuku Ku
2022-12-30
Recruiting
AstraZeneca
Phase 3
3,527
Chiba, Fukuoka, Gifu, Ginowan-shi, Hanyu-shi, Hiroshima, Hitachi-shi, Isehara-shi
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Aichi, Akita, Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima
2022-12-05
Recruiting
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Active, closed
Hoffmann-La Roche
Phase 3
122
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Miyagi
2022-09-27
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka-ken, Gifu, Hachiōji, Hamamatsu, Hirosaki
2022-09-19
Active, closed
GlaxoSmithKline
Phase 3
110
Aomori, Chiba, Gifu, Hyōgo, Miyagi, Tokyo, Wakayama, Yamanashi
2022-09-06
Active, closed
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
DrugAnakinra
Swedish Orphan Biovitrum
Phase 3
15
Fukushima, Kobe, Yokohama, Matsumoto, Bunkyō-Ku, Shinjuku-Ku, Gifu
2022-08-24
Recruiting
Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis
NCT05451901Pancreatic Fluid Collection, Walled-off Necrosis, Pancreatitis, Acute Necrotizing, Pancreatic Pseudocyst
Tokyo University
Not applicable
70
Bunkyō-Ku, Aichi, Chiba, Gifu, Hyōgo, Kagawa, Kagoshima, Kamogawa
2022-07-29
Active, closed
Novo Nordisk A/S
Observational
200
Amagasaki-shi, Hyogo, Chuo-shi, Yamanashi-ken, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka, Gifu, Goshogawara-shi, Aomori-ken, Gunma
2022-02-03
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasaki, Osaka, Ōita
2022-01-15
Active, closed
GlaxoSmithKline
Phase 2
360
Gifu, Hiroshima, Hokkaido, Ishikawa, Kagawa, Kumamoto, Miyagi, Niigata
2021-12-14
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Chiba, Kashiwa-shi, Gifu, Ota-shi, Akashi-shi, Kasama-Shi, Kita-Gun Miki-Cho, Yokohama-Shi Asahi-Ku
2021-12-02
Active, closed
H. Lundbeck A/S
Phase 2
64
Toyoake, Gifu, Sendai
2021-11-16
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Fukuoka, Gifu, Higashiibaraki-gun, Isehara, Kamakura-shi, Kashiwa, Koshigaya, Kumamoto
2021-10-14
Active, closed
Daiichi Sankyo
Phase 3
490
Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama
2021-05-21
Active, closed
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Bunkyo-ku, Tokyo, Fukui-shi, Fukui, Fukushima, Gifu, Hamamatsu-shi, Shizuoka, Hatsukaichi-shi, Hiroshima, Hiroshima-shi, Hiroshima, Izunokuni-shi, Shizuoka
2021-04-01
Recruiting
UCB Biopharma SRL
Phase 3
70
Bunkyō City, Chūō, Gifu, Hiroshima, Kodaira-shi, Kōshi, Kyoto, Nagoya
2021-03-11
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki
2021-02-01
Active, closed
Pullback Pressure Gradient (PPG) Global Registry
NCT04789317Chronic Coronary Insufficiency, Non ST Elevation Myocardial Infarction
VZW Cardiovascular Research Center Aalst
Observational
982
Aichi, Gifu, Tokyo
2020-12-23
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Active, closed
GlaxoSmithKline
Phase 3
325
Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido
2020-04-02
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Nagoya, Gifu, Himeji, Tokyo, Kumamoto, Sendai, Okayama, Toyama
2020-01-17
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tōon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Recruiting
National Cancer Center Hospital East
Phase 3
110
Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa
2019-10-01
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 2/3
27
Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Kanagawa, Kumamoto, Okayama
2019-09-01
Recruiting
Insel Gruppe AG, University Hospital Bern
Not applicable
104
Ageo, Gifu, Nagano, Osaka, Saitama, Sapporo
2019-05-28
Recruiting
Novartis Pharmaceuticals
Observational
700
Nagakute-shi, Toyoake-shi, Chiba, Kurume-shi, Gifu, Sapporo, Kita-gun, Yokohama
2018-09-25
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Asahikawa, Bunkyō City, Chiba, Chikushino-shi, Fukuoka, Gifu, Hachiōji, Hamamatsu
2018-04-13
Active, closed
AbbVie
Phase 2
156
Nagoya, Kamogawa-shi, Matsuyama, Gifu
2018-04-02
Recruiting
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
NCT04706234Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
Kliniken Beelitz GmbH
Observational
350
Gifu
2017-09-01
Active, closed
Hoffmann-La Roche
Phase 3
154
Chiba, Gifu, Saitama
2015-02-02
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Akita, Fukuoka, Gifu, Hakodate, Hiroshima, Hokkaido, Kanazawa, Kashiwa
2013-10-14
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–103 of 103
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-japan/city/gifu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 103 of those studies with a site in Gifu.

How many clinical trials are recruiting in Gifu?

47 of the 103 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 52 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gifu), 103 studies
PhaseStudiesRecruitingShare
Phase 3592757.3%
Phase 216815.5%
Observational1059.7%
Not applicable847.8%
Phase 2/3302.9%
Phase 4312.9%
Phase 1211.9%
Phase 1/2211.9%

Most active sponsors

Lead sponsors with the most studies (Gifu)
Lead sponsorStudiesRecruiting
GlaxoSmithKline124
Janssen Research & Development, LLC124
AstraZeneca96
Hoffmann-La Roche51
Novartis Pharmaceuticals53
AbbVie41
Daiichi Sankyo42
Tokyo University42
Eli Lilly and Company32
Aichi Medical University22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.